CLAIMS

We claim:

1. A composition of formula (1)



(1)

wherein B is adenin-9-yl and R independently is -H or -CH_2-O-C(O)-O-$CH(CH_3)_2$, but at least one R is -CH_2-O-C(O)-O-$CH(CH_3)_2$.

2. The composition of claim 1 wherein both R are -CH_2-O-C(O)-O-$CH(CH_3)_2$.

3. The composition of claim 1 wherein the composition is a crystalline solid.

4. The composition of claim 1 wherein the compound is enriched or resolved at the carbon atom chiral center (*).

5. The composition of claim 1 having an X-ray powder diffraction spectrum peak using Cu-Kα radiation, expressed in degrees 2θ at about 25.0.

6. A composition comprising the composition of claim 1 and an acceptable excipient.

7. A composition comprising a lithium alkoxide and a 9-(2-hydroxypropyl)adenine solution.

8. A composition comprising an (*R,S*)-PMPA solution at a pH of about 2.7-3.5 wherein the solution has less than about 0.1 g/mL (*R,S*)-PMPA and wherein about 90-94% of the PMPA is in the (*R*) configuration.

9. A method comprising orally administering to a patient infected with virus or at risk to viral infection a therapeutically effective amount of a composition of claim 1.

10. A method comprising contacting bis(POC)PMPA with fumaric acid .

11. The method of claim 10 wherein the fumaric acid is dissolved in 2-propanol.

12. A method comprising mixing a lithium alkoxide with a 9-(2-hydroxypropyl)adenine solution.

13. The method of claim 12 wherein the lithium alkoxide is an alkoxide selected from the group consisting of methoxide, ethoxide, *n*-propoxide, *i*-propoxide, *n*-butoxide, *i*-butoxide, *t*-butoxide, neopentoxide, *n*-pentoxide, *i*-pentoxide or *n*-hexoxide, *n*-heptoxide, 2-heptoxide, *n*-octoxide, 2-octoxide, typically *t*-butoxide or *i*-propoxide.

14. The method of claim 13 wherein the lithium alkoxide is lithium *t*-butoxide or lithium *i*-propoxide.

15. A method comprising adjusting the pH of a solution comprising less than about 0.08 g/mL (*R,S*)-PMPA wherein about 90-94% of the PMPA is in the (*R*) configuration to a pH of about 2.7-3.5.

16. A composition comprising a tablet containing 9-[2-(*R*)-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinoyl]methoxy]propyl]-adenine•fumaric acid (1:1), pregelatinized starch, croscarmellose sodium, lactose monohydrate and magnesium stearate.

17. The composition of claim 16 wherein the 9-[2-(*R*)-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinoyl]methoxy]propyl]-adenine•fumaric acid (1:1) is crystalline.

18. The composition of claim 16 wherein the tablet contains 75 mg 9-[2-(*R*)-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinoyl]methoxy]propyl]-adenine•fumaric acid (1:1), 11 mg pregelatinized starch, 8.8 mg croscarmellose sodium, 123.6 mg lactose monohydrate and 2.2 mg magnesium stearate.

19. A product produced by the process of preparing wet granules from a mixture comprising a liquid, 9-[2-(*R*)-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinoyl]methoxy]propyl]-adenine•fumaric acid (1:1) and a pharmaceutically acceptable excipient.

20. The product of claim 19, wherein the liquid is water and the process optionally further comprises drying the wet granules.

33